JPWO2013118773A1 - 特発性炎症性筋疾患の予防又は治療剤 - Google Patents
特発性炎症性筋疾患の予防又は治療剤 Download PDFInfo
- Publication number
- JPWO2013118773A1 JPWO2013118773A1 JP2013557547A JP2013557547A JPWO2013118773A1 JP WO2013118773 A1 JPWO2013118773 A1 JP WO2013118773A1 JP 2013557547 A JP2013557547 A JP 2013557547A JP 2013557547 A JP2013557547 A JP 2013557547A JP WO2013118773 A1 JPWO2013118773 A1 JP WO2013118773A1
- Authority
- JP
- Japan
- Prior art keywords
- myopathy
- muscle
- idiopathic inflammatory
- valine
- leucine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000002481 Myositis Diseases 0.000 title claims abstract description 104
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 title claims abstract description 74
- 239000003814 drug Substances 0.000 title claims abstract description 47
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 14
- 230000003449 preventive effect Effects 0.000 title claims abstract description 11
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 55
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 55
- 239000004474 valine Substances 0.000 claims abstract description 55
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 52
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 52
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 52
- 229960000310 isoleucine Drugs 0.000 claims abstract description 52
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 52
- 201000009623 Myopathy Diseases 0.000 claims abstract description 46
- 238000011282 treatment Methods 0.000 claims abstract description 35
- 239000004480 active ingredient Substances 0.000 claims abstract description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 58
- 239000000203 mixture Substances 0.000 claims description 39
- 201000001981 dermatomyositis Diseases 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 18
- 201000000585 muscular atrophy Diseases 0.000 claims description 16
- 208000005987 polymyositis Diseases 0.000 claims description 16
- 208000010428 Muscle Weakness Diseases 0.000 claims description 15
- 206010028372 Muscular weakness Diseases 0.000 claims description 15
- 206010028289 Muscle atrophy Diseases 0.000 claims description 14
- 230000020763 muscle atrophy Effects 0.000 claims description 14
- 208000021642 Muscular disease Diseases 0.000 claims description 12
- 241000282414 Homo sapiens Species 0.000 claims description 6
- 201000008319 inclusion body myositis Diseases 0.000 claims description 6
- 208000027932 Collagen disease Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000012528 Juvenile dermatomyositis Diseases 0.000 claims 1
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 description 56
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 36
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 36
- 229960005205 prednisolone Drugs 0.000 description 33
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 33
- 229940079593 drug Drugs 0.000 description 30
- 150000005693 branched-chain amino acids Chemical class 0.000 description 28
- 210000001087 myotubule Anatomy 0.000 description 27
- 206010061218 Inflammation Diseases 0.000 description 25
- 230000004054 inflammatory process Effects 0.000 description 24
- 150000003431 steroids Chemical class 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 230000003387 muscular Effects 0.000 description 16
- 239000003981 vehicle Substances 0.000 description 13
- 150000003839 salts Chemical group 0.000 description 12
- 230000003053 immunization Effects 0.000 description 11
- 238000002649 immunization Methods 0.000 description 11
- -1 and in addition Substances 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 210000003194 forelimb Anatomy 0.000 description 9
- 230000008595 infiltration Effects 0.000 description 9
- 238000001764 infiltration Methods 0.000 description 9
- 239000003018 immunosuppressive agent Substances 0.000 description 8
- 210000004969 inflammatory cell Anatomy 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 101710117545 C protein Proteins 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 229960003444 immunosuppressant agent Drugs 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 206010003694 Atrophy Diseases 0.000 description 5
- 230000037444 atrophy Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 4
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 210000003314 quadriceps muscle Anatomy 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 102100025014 E3 ubiquitin-protein ligase TRIM63 Human genes 0.000 description 2
- 101710164910 E3 ubiquitin-protein ligase TRIM63 Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 241000978776 Senegalia senegal Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002519 isoleucine derivatives Chemical class 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 150000003680 valines Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
[1]イソロイシン、ロイシンおよびバリンを有効成分として含有する、特発性炎症性筋疾患の予防又は治療剤;
[2]特発性炎症性筋疾患が、多発性筋炎、皮膚筋炎、筋症状のない皮膚筋炎、小児皮膚筋炎、悪性腫瘍に合併する筋炎、他の膠原病に合併する筋炎、及び封入体筋炎からなる群より選択される、[1]に記載の剤;
[3]筋組織の炎症を抑制することを特徴とする、[1]又は[2]に記載の剤;
[4]筋萎縮および/または筋力低下を改善することを特徴とする、[1]〜[3]のいずれかに記載の剤;
[5]イソロイシン、ロイシンおよびバリンの重量比が、1:1〜3:0.5〜2.0である、[1]〜[4]のいずれかに記載の剤;
[6]ヒトに対する1日あたりの投与量が、イソロイシン、ロイシンおよびバリンの合計量として3〜90gである、[1]〜[5]のいずれかに記載の剤;
[7][1]〜[6]のいずれかに記載の剤、及び薬学的に許容される担体を含む、医薬組成物;
[8]イソロイシン、ロイシンおよびバリンからなる、特発性炎症性筋疾患の予防又は治療剤;
[9][8]に記載の剤、及び薬学的に許容される担体からなる医薬組成物;
[10]イソロイシン、ロイシンおよびバリンを有効成分として含有する組成物を、投与対象に投与することを含む、特発性炎症性筋疾患の予防又は改善方法;
[11]イソロイシン、ロイシンおよびバリンを有効成分として含有する組成物を、投与対象に投与することを含む、筋組織の炎症を抑制することを特徴とする、「10」に記載の方法;
[12]イソロイシン、ロイシンおよびバリンを有効成分として含有する組成物を、投与対象に投与することを含む、筋萎縮および/または筋力低下を改善することを特徴とする、[10]に記載の方法;
[13]イソロイシン、ロイシンおよびバリンの重量比が1:1〜3:0.5〜2.0である、[10]〜[12]のいずれかに記載の方法;
[14]ヒトに対する1日あたりの投与量が、イソロイシン、ロイシンおよびバリンの合計量として3〜90gである、[10]〜[13]のいずれかに記載の方法;
[15]特発性炎症性筋疾患が、治療中にステロイドミオパチーを合併する特発性炎症性筋疾患である、[1]〜[6]のいずれかに記載の剤;
[16][15]に記載の剤、及び薬学的に許容される担体を含む、医薬組成物;
[17]特発性炎症性筋疾患が、治療中にステロイドミオパチーを合併する特発性炎症性筋疾患である、[8]に記載の剤;
[18][17]に記載の剤、及び薬学的に許容される担体を含む、医薬組成物;
[19]特発性炎症性筋疾患が、治療中にステロイドミオパチーを合併する特発性炎症性筋疾患である、[10]〜[14]のいずれかに記載の方法。
C−protein誘導型マウス筋炎モデル(C−protein−induced Myositis:CIM)を用いて、筋組織の炎症に与えるBCAAの効果を検討した。C57BL/6マウス(メス、8週齢)に抗原免疫を行うため、200μg C−proteinと100μg結核死菌(Mycobacterium butyricum)とを含み、Complete Freund’s adjuvant(CFA)を成分とするアジュバントを後肢足底および尾根部に、C−proteinを含まないCFAを前肢根部に皮内注射し、0.25μgの百日咳毒素(Pertussis toxin)を腹腔内注射した。抗原を免疫しないAdjuvant controlには、CFAを同じ部位に皮内注射した。免疫3日後より、0.75g/kg BCAA(イソロイシン、ロイシンおよびバリン(重量比としてイソロイシン:ロイシン:バリン=1:2:1.2)の配合物)、又は20mg/kg Prednisolone(PSL)を連日経口投与し、それぞれBCAA投与群、PSL投与群とした。また、BCAA等の代わりに0.5%メチルセルロース及び5%γシクロデキストリンを経口投与し、Vehicle投与群とした。免疫21日後に筋肉を採取し、大腿四頭筋および屈筋の炎症の程度を炎症スコアにより評価した。炎症スコアは、HE染色した筋切片内で炎症細胞の浸潤と筋線維壊死とを認める領域の筋線維数を以下の基準に従ってスコア化し、大腿四頭筋と屈筋とのスコアの平均値として求めた。
スコア化方法:Grade 0 = 浸潤なし, Grade 1 = 1線維, Grade 2 = 2−5線維, Grade 3 = 6−15線維, Grade 4 = 16−30線維, Grade 5 =31−100線維, Grade 6 = 101線維以上。同一筋肉内の複数部位に同スコアの浸潤が見られた場合は、スコアに0.5を加えた。
結果を図1に示す。C−protein誘導型マウス筋炎モデル(CIMマウス)のVehicle投与群で見られる高い炎症スコアは、PSL投与群とBCAA投与群にて有意に抑制された。これにより、BCAAは抗炎症作用を有することが示された。CIMマウスは多発性筋炎のモデルマウスと考えられていることから、BCAAは多発性筋炎の治療等に対して有用であることが示唆された。
免疫21日後のCIMマウス及びコントロールマウス(Ctrl)から大腿四頭筋、屈筋、および上腕三頭筋を採取し、筋重量を測定した。結果を図2に示す。いずれの筋肉もCtrl群に比較してCIMマウスのVehicle投与群にて筋重量の低下が見られ、PSL投与群では改善が見られないものの、BCAA投与群では改善された。
免疫20日後に動物用握力計MK−380CM/R(室町機械)を用いて各マウスの前肢筋力を測定した。測定は各個体につき6回行い、その平均値を求めた。結果を図3に示す。Ctrl群に比べてCIMマウスのVehicle投与群では筋力の低下が見られ、PSL投与群では改善効果が弱いが、BCAA投与群ではほぼ正常レベルまで改善された。
ステロイド筋症は速筋線維(MHC IIB陽性線維)に優位に生じることから、CIMマウスの筋線維の萎縮を筋線維断面積を計測することにより評価した。免疫21日後に採取した上腕三頭筋の切片の速筋線維と筋線維境界部とを、anti−MHC IIB抗体およびanti−Laminin抗体(Sigma)を用いた免疫蛍光染色により標識し、MHC IIB陽性筋線維の断面積をImage Jソフトウェア(NIH)を用いて計測した。筋線維面積の分布をヒストグラムにして図4に示す。Ctrl群に比べてCIMマウスのVehicle投与群では筋線維の萎縮を示すヒストグラムの左側へのシフトが見られ、PSL投与群ではその傾向がさらに強かった。これらに対してBCAA投与群では、細い筋線維の割合の減少と太い筋線維の割合の増加が見られ、筋線維萎縮の改善について部分的な効果が得られた。
実施例1に記載の方法に従って、0.25g/kg BCAA+20mg/kg PSL、0.75g/kg BCAA+20mg/kg PSL、2.25g/kg BCAA+20mg/kg PSL(各BCAAは、イソロイシン、ロイシンおよびバリン(重量比としてイソロイシン:ロイシン:バリン=1:2:1.2)の配合物)、又は20mg/kg PSLを連日経口投与し、それぞれPSL単独投与群、PSL+BCAA併用投与群とした。また、BCAA等の代わりに0.5%メチルセルロース及び5%γシクロデキストリンを経口投与し、Vehicle投与群とした。
実施例1に記載の評価法によって得られた結果を図5に示す。BCAA+PSL併用投与群では、炎症スコアにおいてBCAAの投与量が異なるBCAA+PSL併用投与群のいずれでも、PSL単独投与群に比してより炎症を抑制する傾向が見られた。
実施例5における免疫21日後のCIMマウス及びコントロールマウス(Ctrl)から大腿四頭筋、大腿屈筋、および上腕三頭筋を採取し、筋重量を測定した。結果を図6に示す。PSL単独投与群では、筋重量の増加が認められなかったのに対し、BCAA+PSL併用投与群では、筋重量の増加が投与量に依存して認められた。
実施例5における免疫20日後に動物用握力計MK−380CM/R(室町機械)を用いて各マウスの前肢筋力を測定した。測定は各個体につき6回行い、その平均値を求めた。結果を図7に示す。PSL単独投与群では、前肢筋力の増加が認められなかったのに対し、BCAA+PSL併用投与群では、前肢筋力の増加が投与量に依存して認められた。
従って、本発明は特発性炎症性筋疾患及び治療中にステロイドミオパチーを合併する特発性炎症性筋疾患の予防又は治療のための医薬として有用である。
Claims (13)
- イソロイシン、ロイシンおよびバリンを有効成分として含有する、特発性炎症性筋疾患の予防又は治療剤。
- 特発性炎症性筋疾患が、多発性筋炎、皮膚筋炎、筋症状のない皮膚筋炎、小児皮膚筋炎、悪性腫瘍に合併する筋炎、他の膠原病に合併する筋炎、及び封入体筋炎からなる群より選択される、請求項1に記載の剤。
- 筋組織の炎症を抑制することを特徴とする、請求項1又は2に記載の剤。
- 筋萎縮および/または筋力低下を改善することを特徴とする、請求項1〜3のいずれか1項に記載の剤。
- イソロイシン、ロイシンおよびバリンの重量比が、1:1〜3:0.5〜2.0である、請求項1〜4のいずれか1項に記載の剤。
- ヒトに対する1日あたりの投与量が、イソロイシン、ロイシンおよびバリンの合計量として3〜90gである、請求項1〜5のいずれか1項に記載の剤。
- イソロイシン、ロイシンおよびバリンを有効成分として含有する組成物を、投与対象に投与することを含む、特発性炎症性筋疾患の予防又は改善方法。
- イソロイシン、ロイシンおよびバリンを有効成分として含有する組成物を、投与対象に投与することを含む、筋組織の炎症を抑制することを特徴とする、請求項7に記載の方法。
- イソロイシン、ロイシンおよびバリンを有効成分として含有する組成物を、投与対象に投与することを含む、筋萎縮および/または筋力低下を改善することを特徴とする、請求項7に記載の方法。
- イソロイシン、ロイシンおよびバリンの重量比が1:1〜3:0.5〜2.0である、請求項7〜9のいずれか1項に記載の方法。
- ヒトに対する1日あたりの投与量が、イソロイシン、ロイシンおよびバリンの合計量として3〜90gである、請求項7〜10のいずれか1項に記載の方法。
- 特発性炎症性筋疾患が、治療中にステロイドミオパチーを合併する特発性炎症性筋疾患である、請求項1〜6のいずれか1項に記載の剤。
- 特発性炎症性筋疾患が、治療中にステロイドミオパチーを合併する特発性炎症性筋疾患である、請求項7〜11のいずれか1項に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013557547A JP6145778B2 (ja) | 2012-02-06 | 2013-02-06 | 特発性炎症性筋疾患の予防又は治療剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012023521 | 2012-02-06 | ||
JP2012023521 | 2012-02-06 | ||
PCT/JP2013/052730 WO2013118773A1 (ja) | 2012-02-06 | 2013-02-06 | 特発性炎症性筋疾患の予防又は治療剤 |
JP2013557547A JP6145778B2 (ja) | 2012-02-06 | 2013-02-06 | 特発性炎症性筋疾患の予防又は治療剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2013118773A1 true JPWO2013118773A1 (ja) | 2015-05-11 |
JP6145778B2 JP6145778B2 (ja) | 2017-06-14 |
Family
ID=48947534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013557547A Expired - Fee Related JP6145778B2 (ja) | 2012-02-06 | 2013-02-06 | 特発性炎症性筋疾患の予防又は治療剤 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20140343148A1 (ja) |
EP (1) | EP2813224A4 (ja) |
JP (1) | JP6145778B2 (ja) |
KR (1) | KR20140121475A (ja) |
AU (2) | AU2013218690A1 (ja) |
CA (1) | CA2863809A1 (ja) |
WO (1) | WO2013118773A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013148328A1 (en) | 2012-03-26 | 2013-10-03 | Pronutria, Inc. | Nutritive proteins and methods |
EP2831102A4 (en) | 2012-03-26 | 2015-12-02 | Pronutria Inc | NUTRIENT FRAGMENTS, NUTRIENT PROTEINS AND METHODS |
AU2013240183B2 (en) | 2012-03-26 | 2016-10-20 | Axcella Health Inc. | Charged nutritive proteins and methods |
AU2013240184B2 (en) | 2012-03-26 | 2017-05-25 | Axcella Health Inc. | Nutritive fragments, proteins and methods |
EP3738590A1 (en) * | 2013-07-31 | 2020-11-18 | Leeds Beckett University | Dietary supplement comprising amino acids for the treatment of sarcopenia |
CN107223020A (zh) | 2013-09-25 | 2017-09-29 | 胺细拉健康公司 | 用于预防和治疗糖尿病和肥胖症的组合物和制剂及其产生和用于葡萄糖和卡路里控制的方法 |
WO2016205397A2 (en) * | 2015-06-15 | 2016-12-22 | Klibanov Alexander L | Target-specific delivery of therapeutic agents |
JP7077235B2 (ja) * | 2016-12-05 | 2022-05-30 | 大塚製薬株式会社 | 筋萎縮抑制組成物 |
US20210260010A1 (en) * | 2018-06-20 | 2021-08-26 | Axcella Health Inc. | Compositions and methods for the reduction or treatment of inflammation |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07118150A (ja) * | 1993-08-31 | 1995-05-09 | Yoshiaki Akiyama | 分枝鎖アミノ酸を有効成分とする、呈味の調整された経口投与薬 |
WO2002060431A1 (fr) * | 2001-01-30 | 2002-08-08 | Ajinomoto Co., Inc. | Medicaments therapeutiques/prophylactiques contre des maladies inflammatoires |
WO2005055997A1 (ja) * | 2003-12-15 | 2005-06-23 | Ajinomoto Co., Inc. | 炎症性疾患の治療及び予防用医薬組成物 |
WO2008072663A1 (ja) * | 2006-12-12 | 2008-06-19 | Ajinomoto Co., Inc. | ステロイド療法における副作用の改善・抑制用組成物 |
JP2009517473A (ja) * | 2005-11-30 | 2009-04-30 | ネステク ソシエテ アノニム | 筋肉損失の治療のための方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3617102B2 (ja) | 1995-01-27 | 2005-02-02 | 味の素株式会社 | ヒト筋肉疲労の早期回復効果を有するアミノ酸栄養組成物 |
US20050101605A1 (en) * | 2003-11-07 | 2005-05-12 | Ahmed Salah U. | Oral liquid formulations of methotrexate |
JP2012023521A (ja) | 2010-07-14 | 2012-02-02 | Funai Electric Co Ltd | テレビジョン受像機及び録画システム |
-
2013
- 2013-02-06 KR KR20147024903A patent/KR20140121475A/ko not_active Application Discontinuation
- 2013-02-06 CA CA 2863809 patent/CA2863809A1/en not_active Abandoned
- 2013-02-06 WO PCT/JP2013/052730 patent/WO2013118773A1/ja active Application Filing
- 2013-02-06 JP JP2013557547A patent/JP6145778B2/ja not_active Expired - Fee Related
- 2013-02-06 AU AU2013218690A patent/AU2013218690A1/en not_active Abandoned
- 2013-02-06 EP EP13747280.9A patent/EP2813224A4/en not_active Withdrawn
-
2014
- 2014-08-05 US US14/451,736 patent/US20140343148A1/en not_active Abandoned
-
2017
- 2017-02-13 US US15/430,796 patent/US20170151200A1/en not_active Abandoned
- 2017-12-19 AU AU2017279592A patent/AU2017279592A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07118150A (ja) * | 1993-08-31 | 1995-05-09 | Yoshiaki Akiyama | 分枝鎖アミノ酸を有効成分とする、呈味の調整された経口投与薬 |
WO2002060431A1 (fr) * | 2001-01-30 | 2002-08-08 | Ajinomoto Co., Inc. | Medicaments therapeutiques/prophylactiques contre des maladies inflammatoires |
WO2005055997A1 (ja) * | 2003-12-15 | 2005-06-23 | Ajinomoto Co., Inc. | 炎症性疾患の治療及び予防用医薬組成物 |
JP2009517473A (ja) * | 2005-11-30 | 2009-04-30 | ネステク ソシエテ アノニム | 筋肉損失の治療のための方法 |
WO2008072663A1 (ja) * | 2006-12-12 | 2008-06-19 | Ajinomoto Co., Inc. | ステロイド療法における副作用の改善・抑制用組成物 |
Non-Patent Citations (3)
Title |
---|
SHIMIZU,N. ET AL: "Crosstalk between Glucocorticoid Receptor and Nutritional Sensor mTOR in Skeletal Muscle", CELL METABOLISM, vol. 13, JPN6013011529, 2011, pages 170 - 182, ISSN: 0003418358 * |
SUGIHARA,T. ET AL: "A New Murine Model to Define the Critical Pathologic and Therapeutic Mediators of Polymyositis", ARTHRITIS & RHEUMATISM, vol. 56, no. 4, JPN6013011530, 2007, pages 1304 - 1314, XP055160849, ISSN: 0003526504, DOI: 10.1002/art.22521 * |
田伏洋子 他: "筋炎の筋症状とその評価法", 月刊リウマチ科, vol. 26, no. 5, JPN6013011531, 2001, pages 420 - 427, ISSN: 0003418357 * |
Also Published As
Publication number | Publication date |
---|---|
US20140343148A1 (en) | 2014-11-20 |
AU2013218690A1 (en) | 2014-09-25 |
EP2813224A4 (en) | 2015-06-24 |
EP2813224A1 (en) | 2014-12-17 |
AU2017279592A1 (en) | 2018-01-18 |
KR20140121475A (ko) | 2014-10-15 |
JP6145778B2 (ja) | 2017-06-14 |
WO2013118773A1 (ja) | 2013-08-15 |
CA2863809A1 (en) | 2013-08-15 |
US20170151200A1 (en) | 2017-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6145778B2 (ja) | 特発性炎症性筋疾患の予防又は治療剤 | |
US10966962B2 (en) | Method for treating neurodegenerative diseases | |
RU2012117563A (ru) | Режим дозирования модулятора рецептора s1p | |
WO2003103659A1 (ja) | 過活動膀胱治療剤 | |
US9271948B2 (en) | Agent for improving vesicourethral dyssynergia | |
WO2022253034A1 (zh) | 吡咯并嘧啶类化合物的用途 | |
JP3415643B2 (ja) | 筋ジストロフィー症治療薬 | |
EA034394B1 (ru) | Биотин для лечения амиотрофического латерального склероза | |
CN110325214A (zh) | 用于预防和治疗神经元损伤的低剂量药物组合 | |
JP2012158603A (ja) | 耐糖能異常用医薬組成物及び飲食品 | |
WO2022135462A1 (zh) | Magl抑制剂的医药用途 | |
CN1299676C (zh) | 一种抗缺氧药物组合物 | |
CN112641765B (zh) | 丙泊酚的抗疲劳制药用途 | |
WO2005055997A1 (ja) | 炎症性疾患の治療及び予防用医薬組成物 | |
US20140100165A1 (en) | Prevention of kidney injury or disease | |
JP6935930B2 (ja) | 生薬成分を含む肺高血圧症の予防又は治療剤 | |
JPH11171763A (ja) | 肝疾患治療剤 | |
US7560485B2 (en) | Method for treating intermittent claudication comprising the administration of propionyl L-carnitine and a concomitant physical training | |
CN115364195A (zh) | Thiostrepton在制备预防和治疗硬皮病的药物中的应用 | |
CN115715191A (zh) | 排尿症状治疗剂 | |
CN109125308A (zh) | 秋水仙碱在预防和治疗缺血性脑血管疾病的新用途 | |
WO2016208045A1 (ja) | 脊髄小脳変性症における運動失調の治療剤の投与レジメン | |
Wang et al. | A double-blind, placebo-controlled study of house dust mite immunotherapy in asthmatic patients in China | |
JP2016102068A (ja) | 鯨筋肉抽出物からなる中長期記憶障害予防改善剤 | |
WO2012110946A1 (en) | Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160203 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20160531 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160531 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20160615 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161018 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170217 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170328 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170421 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6145778 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |